WTSP – Sept. 6
Since then, they've spent much of their time at Moffitt Cancer Center and are renting a temporary apartment so Laurie can be close by.
Bay News 9 – Sept. 6
Laurie Vos underwent a stem cell transplant at Moffitt Cancer Center this week. She was diagnosed with multiple myeloma several months ago, which is a cancer of the plasma cells and bone marrow.
Orlando Sentinel – Sept. 6
Donors to Stand Up To Cancer this year will be helping Jan Freeland, ... “Stand Up To Cancer has been essential to my treatment because they are funding ... Up To Cancer Lung TIL Catalyst trial at Moffitt Cancer Center in Tampa.
OncLive – Sept. 6
Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).
WFMJ – Sept. 7
Dr. Jacques Fontaine, a thoracic surgeon who started the Mesothelioma Research and Treatment Center at Moffitt Cancer Center in Tampa, remembers Dr. Sugarbaker as a “mentor of mentors”. Fontaine holds that “His vision, focus and dedication to advancing the treatment of mesothelioma have influenced an entire generation of thoracic surgeons.” Also posted to RFD-TV, KAKE, WFXG, KFBB, KULR, Olympia Journal, WMBF, WICZ and KWES.
OncLive – Sept. 5
Novel treatment regimens are showing potential in patients with follicular lymphoma, especially those without a chemotherapeutic backbone, explained Celeste Bello, MD, a hematologist/oncologist at Moffitt Cancer Center.
OncLive – Sept. 5
Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor (CAR) T-cell therapy.
AJMC – Sept. 5
As Todd C. Knepper, PharmD, and Howard L. McLeod, PharmD, both of Florida’s Moffitt Cancer Center, reported in a comment recently published in Nature, in 1997, 92% of participants in clinical trials for treatments targeting cancer, central nervous system diseases, and heart disease were white.
The Health Site – Sept. 5
Researchers led by Nagi B. Kumar of the Moffitt Cancer Center found that an active component in decaffeinated green tea prevented prostate cancer development in men who have premalignant lesions.
News Medical – Sept. 6
Approaching cancer care from a high-tech angle, a panel moderated by Moffitt Cancer Center Director Thomas A. Sellers, MD, will convene commercial and academic players in the Big Data arena with an eye toward enhancing dialogue and developing stronger linkages that could lead to expanded information-sharing and improved patient care.
OncLive – Sept. 4
Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.
Tampa Bay Times – Sept. 4
More than 400 pillows were delivered to Moffitt Cancer Center, Hope Lodge and Florida Hospital. This summer, new member Barbara Booth alone sewed 290 pillows.
STL News – Sept. 2
Thursday, Florida Governor Rick Scott highlighted more than $300 million invested in Florida’s cancer centers since 2014 while at Moffitt Cancer Center.
Space Coast Daily – Sept. 2
Florida Governor Rick Scott highlighted more than $300 million invested in Florida’s cancer centers since 2014 during a recent visit to the Moffitt Cancer Center.
Cancer Letter – Sept. 1
Moffitt Cancer Center’s chief information security officer will join a group of experts charged with protecting and enhancing national cybersecurity.
News Dog – Sept. 1
Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer. The results, published online by JAMA Oncology, show higher likelihoods of complete response or down-staging associated with a chemotherapeutic combination called ddMVAC.
OncLive – Aug. 31
Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.
OncLive – Aug. 31
Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).
MedPage Today – Aug. 31
In the neoadjuvant setting, rates of downstaging were 52.2% among stage ≥T2 patients treated with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) versus 27.0% in those treated with gemcitabine (Gemzar) plus carboplatin and 41.3% in those who received standard gemcitabine plus cisplatin (P<0.001), reported Scott M. Gilbert, MD, MS, and colleagues from Moffitt Cancer Center in Tampa, Florida.
New Scientist – Aug. 31
“Understanding intra-tumour evolution during cancer therapy is critical for optimising treatment,” says Robert Gatenby of the Moffitt Cancer Center in Tampa, Florida, who has pioneered a game-theory based way of treating prostate cancer according to how it evolves.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.